An Open, Single Centre Pharmacokinetic (Phase 1) Study of the Biliary Excretion of AZD0837 and Metabolites Following a Single Dose of [3H] AZD0837 Given in the Duodenum Via a Loc-I-Gut Catheter to Young Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 09 Dec 2009
At a glance
- Drugs AZD 0837 (Primary)
- Indications Thromboembolism
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 10 Mar 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
- 10 Mar 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 03 Feb 2009 Actual initiation date (Jan 2009) added as reported by ClinicalTrials.gov.